Intersect ENT (Nasdaq:XENT) is defining and delivering novel treatments which are designed to transform the landscape of ENT care. We apply a focused evidence-based approach to solve clinical challenges and improve the quality of life for patients. The company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers. For additional information on the company or the products including risks and benefits please visit www.intersectENT.com